Dr. Maurice Rawlings, MD, a heart surgeon, has written a number of books on the near-death experience and clearly shows from his own practice and the experiences of his patients, that not everyone goes to the light when they die, where there is total love. He has written of many patients being resuscitated on the operating table and speaking about being in hell, where there was a real devil and demons, and where the inhabitants were tormented with fire. Dr. Rawlings writes that these people are a lot more reluctant to talk about it than those who went to the good place. DivineRevelations.info
nanobébé, a brand dedicated to revolutionizing the infant feeding industry, today announced the launch of its much-anticipated sleek and modern ecosystem of health-focused feeding essentials for today’s 21st century parents, poised to be hot baby registry items this year. Breastfeeding moms can rejoice in the company’s flagship Breastmilk Bottle, the first and only baby bottle designed specifically to preserve essential breast milk nutrients. From pumping, storing, warming to feeding, the award-winning nanobébé Breastmilk Bottle protects the breast milk and preserves its nutritional value.
“When moms warm breast milk in the traditional way, there is a good chance that they are unknowingly damaging the nutritional and immunity-boosting properties of the milk. Additionally, the milk is likely heated unevenly, causing hot spots, which can harm the baby,” said Rallie McAllister, MD, MPH, nanobébé SpokesDoctor, family physician and coauthor of The Mommy MD Guide to Your Baby’s First Year. “nanobébé’s bottles are biomedically engineered with a concave shape that spreads the breast milk into a thin layer and allows it to warm at safe temperatures, protecting nutrients from damage and preventing hot spots.” The nanobébé Breastmilk Bottle warms stored breast milk quickly, twice as fast as standard bottles.
To view the multimedia release go to:
https://www.multivu.com/players/English/8260351-nanobebe-infant-breastfeeding-line/
Global specialty plastics provider Eastman demonstrates the dominant performance of next-generation material Eastman MXF221 copolyester as a disinfectant-ready polymer for safer healthcare environments at the Medical Design & Manufacturing (MD&M) West trade show in Anaheim, California, Feb. 6 to 8. The latest advancement in biocompatible medical-grade polymers for medical device housings and hardware, Eastman MXF221 offers unsurpassed chemical compatibility with stringent disinfectants used to combat healthcare-associated infections (HAIs) as well as improved durability and impact strength.
To view the multimedia release go to:
https://www.multivu.com/players/English/8261151-eastman-disinfectant-ready-polymer-mdm-west/
Medical, health, technology, healthcare, treatment, Richard Fechter, interview, trade show, MultiVu 8261151
Four-time PGA TOUR winner Tim Herron is teaming up with Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP), Damon Adamany, MD, of The CORE Institute and the Facts on Hand campaign to educate adults about one of the more common hand conditions. The campaign is raising awareness of Dupuytren’s Contracture, a progressive, potentially disfiguring hand condition affecting a layer of tissue underneath the palms that can cause one or more fingers to move into a bent position so they cannot be straightened.
Dupuytren’s Contracture, sometimes referred to as “Viking Disease,” can make everyday tasks difficult, such as grabbing an object at home, or in Tim Herron’s case, a nine iron from his golf bag. Many people live with the disease without being diagnosed because they mistakenly assume they have arthritis or another hand condition. And because Dupuytren’s Contracture may progress slowly, people may not pay attention to it until they can no longer straighten their fingers, complicating everyday activities.
To view the multimedia release go to:
https://www.multivu.com/players/English/8153851-endo-facts-on-hand-dupuytrens-contracture/
Jason’s Deli and The University of Texas MD Anderson Cancer Center proudly introduce the new Salmon Pacifica Salad as part of an ongoing alliance to raise money to help end cancer for patients and families around the world.
Now through April 2018, 50 cents from the sale of every Salmon Pacifica Salad at participating Jason’s Deli restaurants will be donated to MD Anderson to support cancer prevention research and programs.
To view the multimedia release go to:
https://www.multivu.com/players/English/8102251-jasons-deli-md-anderson-cancer-center-salmon-pacifica-salad/
The following statement is being issued by Block & Leviton LLP, Finkelstein Thompson LLP and Green & Noblin PC regarding the Drywall Antitrust Litigation.
If you purchased Wallboard INDIRECTLY from one or more of the companies listed below, your rights may be affected by proposed Settlements
A proposed class settlement totaling $5.2 million has been reached with a defendant in In re Domestic Drywall Antitrust Litigation, MDL No. 2437 and 13-MD-2437, pending in the U.S. District Court for the Eastern District of Pennsylvania.
To view the multimedia release go to:
http://www.multivu.com/players/English/7975351-drywall-class-action-settlement/
Eğer kuran şeriatına uymayıp mahkemelerde hakkınızı ararsanız dinden çıkmış sayılırsınız,dinden çıkan birinin cezasıda ölümdür.
Allah; erkeğe, kadının iki misli miras vermenizi emreder. Nisa Suresi 11. ayet
Orbis, the international nonprofit that unites the world in the fight against blindness, is proud to land its new, state-of-the-art Flying Eye Hospital in Shenyang, China this week to commence its first training program, running from September 5 - 23. Six years in the making, the third-generation Flying Eye Hospital is the world’s only mobile ophthalmic teaching hospital on board an MD-10 aircraft, donated by FedEx. Hundreds of experts have come together to combine the latest in avionics, hospital engineering, technology and clinical expertise to make the new Flying Eye Hospital a reality. It features modular design, 3D technology and live broadcast capabilities, which enables Orbis and their expert Volunteer Faculty to train more doctors, nurses and healthcare professionals—ultimately treating more people and restoring their sight.
“Today, I am incredibly proud that our Flying Eye Hospital can get to work on its first program,” Bob Ranck, Orbis CEO and President, said. “It is a testament to the hundreds of volunteers, global corporate partners, governments and other individuals who have worked tirelessly to make this unique aircraft a reality, and we thank them one and all. Our mission at Orbis is to bring the world together to fight blindness, and the Flying Eye Hospital is an important tool for achieving this. It is an equal-parts teacher, envoy and advocate for the right to sight. We are excited to start this new chapter in Orbis history here in Shenyang, China.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7316251-orbis-flying-eye-hospital/
Noted pediatric heart surgeon Dr. Kristine Guleserian has opened up her OR, and her career to author Mark Oristano to create Surgeon’s Story Inside OR 6 With a top Pediatric Heart Surgeon. Dr. Guleserian’s life, training and work are discussed in detail, framed around the incredibly dramatic story of a heart transplant operation for a two-year old girl whose own heart was rapidly dying. Find out more at- http://surgeonsstory.com/ Media Contact: For a review copy of Surgeon’s Story or to schedule an interviewwith Mark Oristano, contact Scott Lorenz of Westwind Communications Book Marketing, 734 667 2090 scottlorenz@westwindcos.com or http://www.book-marketing-expert.com Medical Non-Fiction
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
